Ascletis Pharma Inc. ASCLF
Set alert
0.72 USD 0.00 0.00%
At close · Oct 30
0.72 Day range 0.72
0.72 52-week range 2.50
- YTD
- -51.68%
- 1 year
- -40.00%
- Open
- 0.72
- Prev close
- 0.72
- Mkt cap
- 753.92M
- Vol
- 5.00K
- Avg vol
- 928
- EPS
- -0.08
- P/E
- 0.00
More statistics
- Low
- 0.72
- High
- 0.72
- Earnings
- Aug 31, 2026
2Y chart
Events in this range
- Mar 26, 2025Earnings: -0.02328; estimate -0.02054; surprise -13.34%
- Aug 15, 2025Earnings: -0.01275; estimate -0.01814; surprise 29.71%
- Mar 31, 2026Earnings: -0.04003; estimate -0.04003; surprise 0%
- Aug 31, 2026Earnings: —; estimate -0.02944; surprise —%
Signals (61)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 3 days ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 25, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| RSI: Oversold | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| RSI: Oversold | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| RSI: Overbought | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 7, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
Newest 20 of 61.
Next earnings
Aug 31, 2026
Expected Aug 31, 2026. Consensus EPS estimate -0.02944.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 31, 2026 | Jun 30, 2026 | -0.02944 | — | — | — |
| Mar 31, 2026 | Dec 31, 2025 | -0.04003 | -0.04003 | 0.00 | 0.00% |
| Aug 15, 2025 | Jun 30, 2025 | -0.01814 | -0.01275 | +0.01 | +29.71% |
| Mar 26, 2025 | Mar 31, 2025 | -0.02054 | -0.02328 | 0.00 | -13.34% |
| Aug 30, 2024 | Jun 30, 2024 | -0.01651 | -0.01764 | 0.00 | -6.84% |
| May 22, 2024 | Mar 31, 2024 | 0.00147 | — | — | — |
News
- Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
- Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
- Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
- Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
- Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
- Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
- Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
- Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
- Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Your note
Sign in to keep a note on ASCLF — it syncs with the Stock Master app.